Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milatuzumab in recurrent/refractory multiple myeloma
NCT00421525Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2007
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of milatuzumab in multiple myeloma (MM), sponsored by Gilead Sciences. Primary endpoint: Safety and tolerability of hLL1 at 2 years. Started Jan 2007; status: completed.
02
Drugs
milatuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00421525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421525.